Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. / Schroeder, Patricia E.; Hofland, Kenneth Francis; Jensen, Peter Buhl; Sehested, Maxwell; Langer, Seppo W.; Hasinoff, Brian B.

I: Cancer Chemotherapy and Pharmacology, Bind 53, Nr. 1, 01.2004, s. 91-93.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Schroeder, PE, Hofland, KF, Jensen, PB, Sehested, M, Langer, SW & Hasinoff, BB 2004, 'Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent', Cancer Chemotherapy and Pharmacology, bind 53, nr. 1, s. 91-93. https://doi.org/10.1007/s00280-003-0711-z

APA

Schroeder, P. E., Hofland, K. F., Jensen, P. B., Sehested, M., Langer, S. W., & Hasinoff, B. B. (2004). Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology, 53(1), 91-93. https://doi.org/10.1007/s00280-003-0711-z

Vancouver

Schroeder PE, Hofland KF, Jensen PB, Sehested M, Langer SW, Hasinoff BB. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology. 2004 jan.;53(1):91-93. https://doi.org/10.1007/s00280-003-0711-z

Author

Schroeder, Patricia E. ; Hofland, Kenneth Francis ; Jensen, Peter Buhl ; Sehested, Maxwell ; Langer, Seppo W. ; Hasinoff, Brian B. / Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. I: Cancer Chemotherapy and Pharmacology. 2004 ; Bind 53, Nr. 1. s. 91-93.

Bibtex

@article{36a12e98dac1422e9da561798feb261b,

title = "Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent",

abstract = "Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide. Methods: Etoposide plasma levels were determined by HPLC. Results: The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses. Conclusions: The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.",

keywords = "Dexrazoxane, Etoposide, Pharmacokinetics, Rescue, Toxicity",

author = "Schroeder, {Patricia E.} and Hofland, {Kenneth Francis} and Jensen, {Peter Buhl} and Maxwell Sehested and Langer, {Seppo W.} and Hasinoff, {Brian B.}",

year = "2004",

month = jan,

doi = "10.1007/s00280-003-0711-z",

language = "English",

volume = "53",

pages = "91--93",

journal = "Cancer Chemotherapy and Pharmacology, Supplement",

issn = "0943-9404",

publisher = "Springer",

number = "1",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

AU - Schroeder, Patricia E.

AU - Hofland, Kenneth Francis

AU - Jensen, Peter Buhl

AU - Sehested, Maxwell

AU - Langer, Seppo W.

AU - Hasinoff, Brian B.

PY - 2004/1

Y1 - 2004/1

N2 - Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide. Methods: Etoposide plasma levels were determined by HPLC. Results: The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses. Conclusions: The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.

AB - Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide. Methods: Etoposide plasma levels were determined by HPLC. Results: The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses. Conclusions: The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.

KW - Dexrazoxane

KW - Etoposide

KW - Pharmacokinetics

KW - Rescue

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0742286817&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0711-z

DO - 10.1007/s00280-003-0711-z

M3 - Journal article

C2 - 14574459

AN - SCOPUS:0742286817

VL - 53

SP - 91

EP - 93

JO - Cancer Chemotherapy and Pharmacology, Supplement

JF - Cancer Chemotherapy and Pharmacology, Supplement

SN - 0943-9404

IS - 1

ER -

ID: 248230908